



<i>Application Number</i>	10/526,905
<i>Filing Date</i>	February 23, 2006
<i>First Named Inventor</i>	Colin Watts
<i>Art Unit</i>	1634
<i>Examiner Name</i>	Stephen Thomas Kapushoc
<i>Attorney Docket Number</i>	FBR0002-100

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AA	WO 98/048010	10-29-1998	Callaghan et al.		
	AB	WO 02/071928 A2	09-19-2002	Monaghan et al		
	AC	WO 97/15674	05-1-1997	Watts et al.		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/526,905
Filing Date	February 23, 2006
First Named Inventor	Colin Watts
Art Unit	1634
Examiner Name	Stephen Thomas Kapushoc
Attorney Docket Number	FBR0002-100

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	Bahassi et al., "Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways," <i>Oncogene</i> (2002) 21:6633-6640.	
	AE	Callaghan et al., "Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs," <i>Oncogene</i> (1998) 17:3479-3491.	
	AF	Clancy, Jennifer et al., "EDD, The Human Hyperplastic Discs Gene, Is Amplified ? Overexpressed in Cancer," <i>Oncogene</i> , (2003), vo. 22, no.32, pp.5070-5081.	
	AG	Forozan et al., "Molecular cytogenetic analysis of 11 new breast cancer cell lines," <i>British Journal of Cancer</i> , (1999) 81(8):1328-1334.	
	AH	Fourth Peter MacCallum Institute Symposium "Molecular & Cell Biology of Cancer" Melbourne, Australia, November 8, 2001.	
	AI	Henderson et al., "EDD, the Human Hyperplastic Discs Protein, Has a Role in Progesterone Receptor Coactivation and Potential Involvement in DNA Damage Response," <i>The Journal of Biological Chemistry</i> (2002) 277 (29): 26468-26478.	
	AJ	Honda et al., "Cooperation of HECT-domain Ubiquitin Ligase hHYD and DNA Topoisomerase II-binding Protein for DNA Damage Response," <i>The Journal of Biological Chemistry</i> (2002) 277 (5):3599-3605.	
	AK	Huibregtse et al., "A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase," <i>Proc. Natl. Acad. Sci. USA</i> (1995) 92:2563-2567.	
	AL	Larramendy et al., "Comparative Genomic Hybridization Reveals Complex Genetic Changes in Primary Breast Cancer Tumors and Their Cell Lines," <i>Cancer Genet Cytogenet</i> (2000) 119:132-138.	
	AM	Mansfield et al., "Genetic and Molecular Analysis of hyperplastic discs, a Gene Whose Product Is Required for Regulation of Cell Proliferation in Drosophila melanogaster Imaginal Discs and Germ Cells," <i>Developmental Biology</i> (1994) 165:507-526.	
	AN	Muller et al., "Molecular characterization of a novel rat protein structurally related to poly(A) binding proteins and the 70K protein of the U1 small nuclear ribonucleoprotein particle (snRNP)," <i>Nucleic Acids Research</i> (1992) 20 (7):1471-1475.	
	AO	Richter et al., "Chromosomal Imbalances Are Associated with a High Risk of Progression in Early Invasive (pT1) Urinary Bladder Cancer!," <i>Cancer Research</i> (1999) 59:5687-5691.	
	AP	Saunders et al., "Embryonic lethality in mice with a targeted disruption of EDD, the homologue of the Drosophila melanogaster tumour suppressor gene Hyd," <i>Cancer Research Program, Garvin Institute of Medical Research, Australia</i> , November 8, 2001.	
	AQ	Tosi et al., "Characterization of the Human Myeloid Leukemia-Derived Cell Line GF-D8 by Multiplex Fluorescence In Situ Hybridization, Subtelomeric Probes, and Comparative Genomic Hybridization," <i>Genes, Chromosomes & Cancer</i> (1999) 24:213-221.	

Examiner
SignatureDate
Considered



10-16-06

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JFW

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/526,905	
	Filing Date	February 23, 2006	
	First Named Inventor	Colin Watts	
	Art Unit	1634	
	Examiner Name	Stephen Thomas Kapushoc	
Total Number of Pages in This Submission	6	Attorney Docket Number	FBR0002-100 (122252)

ENCLOSURES (check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Forms PTO SB/08a and SB/08b (1 p.); (14) References Cited; Copy of International Search Report |
|---|--|---|

Remarks

EL 963420785US

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Cozen O'Connor		
Signature			
Printed Name	Mark DeLuca.		
Date	10.12.06	Reg. No.	33,229

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL NO. EL 963420785 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Mark DeLuca	Date	10.12.06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



DOCKET NO: FBR0002-100(122252)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Colin Watts**

Serial No.: **10/526,905**

Group Art Unit: **1634**

Filing Date: **February 23, 2006**

Examiner: **Stephen Thomas Kapushoc**

For: **Novel Diagnostic and Therapeutic Methods and Reagents Therefor**

EXPRESS MAIL LABEL NO: **EV 963420785 US**

DATE OF DEPOSIT: **October 12, 2006**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **before** the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.
- ☐ **after** the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under § 1.114, but before the mailing

date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

or

☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

☐ No fee is owed by the applicant(s).

☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the ☐ first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.

☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p).

☒ Copies of the cited references (except the U.S. Patent Documents) listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are enclosed. Also enclosed is a copy of International Search Report dated May 9, 2005 for International Application No. PCT/AU03/01164.

EXCEPT THAT:

☐ In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) _____ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- ☐ The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in § 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☒ No fee or Statement is required under 37 C.F.R. § 1.97(b) as no first Office Action on the merits has been received by the Applicants.

Respectfully submitted,



Mark DeLuca
Registration No. 33,229

Dated: 10-12-06

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 665-2013 - Facsimile